Source comparison
BPC-157 Dosage Tendon Healing: Protocol Comparison
200–250mcg daily Minor strain, Grade I tear, early-stage tendinopathy Subcutaneous within 1–2cm of injury 4–6 weeks to pain resolution, 6–8 weeks to full tensile strength restoration Appropriate for injuries where imaging shows minimal structural disruption; c
This comparison does not assign a generated winner or score.
- 200–250mcg daily
- Minor strain, Grade I tear, early-stage tendinopathy
- Subcutaneous within 1–2cm of injury
- 4–6 weeks to pain resolution, 6–8 weeks to full tensile strength restoration
- Appropriate for injuries where imaging shows minimal structural disruption; cost-effective starting point for most protocols
- 350–500mcg daily
- Moderate to severe strain, Grade II tear, chronic tendinopathy with imaging-confirmed degeneration
- Subcutaneous injection rotated around injury perimeter
- 6–8 weeks to functional improvement, 8–12 weeks to structural remodeling completion
- Standard research dosage; balance between mechanism saturation and compound cost; most published tendon studies use this range
- 600–1000mcg daily
- Complete rupture (post-surgical), severe chronic tendinopathy unresponsive to lower doses
- Divided doses (AM/PM) at multiple injection sites surrounding injury
- 8–12 weeks minimum; may require extended protocols beyond 12 weeks
- Used in experimental protocols for severe cases; evidence for proportional benefit above 500mcg is limited; higher cost without conclusively faster outcomes
- Oral administration (any dose)
- Not recommended for targeted tendon healing
- Oral capsule or sublingual
- Unreliable; systemic distribution dilutes local concentration
- Bioavailability reduced to 15–20% due to gastric peptidase degradation; ineffective for localized tissue repair despite marketing claims